Cargando…
Assessing trial representativeness using serious adverse events: an observational analysis using aggregate and individual-level data from clinical trials and routine healthcare data
BACKGROUND: The applicability of randomised controlled trials of pharmacological agents to older people with frailty/multimorbidity is often uncertain, due to concerns that trials are not representative. However, assessing trial representativeness is challenging and complex. We explore an approach a...
Autores principales: | Hanlon, Peter, Butterly, Elaine, Shah, Anoop S. V., Hannigan, Laurie J., Wild, Sarah H., Guthrie, Bruce, Mair, Frances S., Dias, Sofia, Welton, Nicky J., McAllister, David A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9615407/ https://www.ncbi.nlm.nih.gov/pubmed/36303169 http://dx.doi.org/10.1186/s12916-022-02594-9 |
Ejemplares similares
-
Treatment effect modification due to comorbidity: Individual participant data meta-analyses of 120 randomised controlled trials
por: Hanlon, Peter, et al.
Publicado: (2023) -
Comorbidity and health-related quality of life in people with a chronic medical condition in randomised clinical trials: An individual participant data meta-analysis
por: Butterly, Elaine W., et al.
Publicado: (2023) -
Representation of people with comorbidity and multimorbidity in clinical trials of novel drug therapies: an individual-level participant data analysis
por: Hanlon, Peter, et al.
Publicado: (2019) -
Correlations between comorbidities in trials and the community: An individual-level participant data meta-analysis
por: Crowther, Jamie, et al.
Publicado: (2023) -
Effect of age, sex, and morbidity count on trial attrition: meta-analysis of individual participant level data from phase 3/4 industry funded clinical trials
por: Lees, Jennifer S, et al.
Publicado: (2022)